Recent price action has seen MXN’s status as the second-best performer year-to-date flip to the worst performer since the beginning of September and the second worst in October.
<p>Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commod
Leave a Comment